Economic Burden of Invasive Meningococcal Infection in Children in the Republic of Belarus
https://doi.org/10.31631/2073-3046-2023-22-6-99-107
Abstract
Relevance Invasive meningococcal infection (IMI) is a significant clinical problem and is associated with a high probability of severe complications and death. Vaccination programs against meningococcus can achieve significant clinical effectiveness and require significant financial costs. This makes it relevant to study the economic burden of meningococcal infection in the conditions of modern healthcare in order to obtain basic data for subsequent research in the field of evaluation of medical technologies.
Aims. To assess the economic burden of IMI in children in the conditions of healthcare in the Republic of Belarus
Material and methods: a retrospective study using the "cost of illness" method was conducted for 22 children hospitalized in the city children's infectious clinical diseases hospital in 2018-2019. All values are presented in belarusian rubles. The average ± standard deviation, minimum – maximum values, median [Q1, Q3], cost shares (%) are calculated for the cost values. The minimum– maximum values and median [Q1, Q3] were calculated for the age of the patients.
Results: taking into account the costs of treatment in healthcare organizations of all patients studied, the share of direct costs of hospitalization was 29.0%, the share of direct costs of diagnosis – 7.2%, the share of direct costs of pharmacotherapy - 8.3%. A significant part of the costs accounted for observations after discharge and amounted to 55.4%.
Conclusion: a retrospective study of the economic burden of MI in the Republic of Belarus using the "cost of illness" method in patients hospitalized in a public health organization demonstrates a significant economic burden of this disease, which in the long term is primarily due to the presence of complications in the patient, as well as the impact of the patient's death on the value of total costs. The data obtained can be used in conducting national research on the evaluation of medical technologies.
About the Authors
E. N. SergienkoBelarus
Katsiaryna N. Serhiyenka – Cand. Sci. (Med.), Associate Professor of department of children infectious diseases
+375 29 773 27 53
Minsk
I. N. Kozhanova
Belarus
Irina N. Kozhanova – Dr. Sci. (Med.), professor of department of clinical pharmacology
+375 29 687 04 01
Minsk
O. N. Romanova
Belarus
Oxana N. Romanova – Dr. Sci. (Med.), professor of department of children infectious diseases
+375 29 653 53 80
Minsk
A. D. Solodov
Belarus
Arthur D. Solodov – pediatric oncologist-hematologist
+375 29 851 17 61
Minsk
P. A. Sсutova
Belarus
Polina A. Skutova – intern doctor
+375 44 731 00 30
Minsk
References
1. Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and metaanalysis. Microbial Pathogenesis.2019;134:103571. https://doi.org/10.1016/j.micpath.2019.103571
2. Martino´n-Torres F. Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements. Journal of Adolescent Health. 2016;59(2):S12-20. https://doi.org/10.1016/j.jadohealth.2016.03.041
3. Olbrich KJ, Muller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers. Infectious Diseases and Therapy. 2018; 7(4):421-38. https://doi.org/10.1007/s40121-018-0213-2
4. Martinón-Torres F. J. Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements. Adolescent Health. 2016;59(2):12-20. https://doi.org/10.1007/s40121-018-0213-2
5. Wang B., Santoreneos R., Gileset L., et al. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine. 2019;37(21):2768-82. doi: 10.1016/j.vaccine.2019.04.020
6. ECDC. Invasive meningococcal disease. Annual Epidemiological Report for 2017. Available at: https://www.ecdc.europa.eu/en/publications-data/invasive-meningococcaldisease-annual-epidemiological-report-2017. Accessed: 26 октября 2023.6.
7. Nuttens C, Findlow J, Balmer P, et al. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. Eurosurveillance. 2022;27(3):2002075. doi: 10.2807/1560-7917.ES.2022.27.3.2002075
8. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2010;10(12):853-61. doi: 10.1016/S1473-3099(10)70251-6
9. Martinón-Torres F. Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements. Adolescent Health. 2016;59(2):S12-20. doi: 10.1016/j.jadohealth.2016.03.041
10. Stein-Zamir C, Shoob H, Sokolov I, et al. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatric Infectious Diseases. 2014;33(7):777-9. doi.org/10.1097/INF.0000000000000282
11. Olbrich KJ, Müller D, Schumacher S, et al. Systematic Review of Invasive Meningococcal Disease: Sequelae and Quality of Life Impact on Patients and Their Caregivers. Infection Diseases Therapy. 2018;7(4):421-38. doi: 10.1007/s40121-018-0213-2
12. Fedorova IV, Sergienko EN, Romanova ON, et al. Meningococcal infection in the Republic of Belarus: from «harmless» carrier to sepsis. Clinical infectology and parasitology. 2022;11(3):181-191. (In Russ).
13. Yagudina RI, Litvinenko MM. Analysis of the «Cost of disease» as a basic method of pharmacoeconomical research at various levels of the healthcare system. Bulletin of the Scientific Center for the Examination of Medical Products. 2014;1:55-59. (In Russ).
14. Davis KL, Misurski D, Miller J, et al. Cost impact of complications in meningococcal disease: evidence from a United States managed care population. Human Vaccine. 2011;7(4):458-65. doi. org/10.4161/hv.7.4.14434
15. Wang B, Haji Ali Afzali H, et al. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. Vaccine. 2014;32(37):4791-8. doi.org/10.1016/j.vaccine.2014.05.069
16. Stoof SP, Rodenburg GD, Knol MJ, et al. Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex. Clinical Infections Diseases. 2015; 61(8):1281-92. doi: 10.1093/cid/civ506
17. Huang L, Heuer OD, Janben S, et al. Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database. PLoS One. 2020;15(1):e0228020. doi: 10.1371/journal.pone.0228020
18. Strifler L, Morris SK, Dang V, et al. The Health Burden of Invasive Meningococcal Disease: A Systematic Review. Pediatric Infectious Diseases Society. 2016 Dec; 5(4):417-30. doi: 10.1093/jpids/piv065
19. Weil-Olivier C, Taha MK, Emery C, et al. Healthcare Resource Consumption and Cost of Invasive Meningococcal Disease in France: A Study of the National Health Insurance Database. Infectious Diseases Therapy. 2021;10(3):1607-23. doi: 10.1007/s40121-021-00468-w
20. Chacon-Cruz E, Lopatynsky-Reyes EZ, Huerta-Garcia G, et al. Economic burden of meningococcal disease in children and adolescents in Tijuana, Mexico. Human Vaccines & Immunotherapeutics. 2022;18(6):2103319. doi: 10.1080/21645515.2022.2103319
21. Christensen H, Irving T, Koch J, et al. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(R) to reduce meningococcal group B disease in Germany. Vaccine. 2016; 34(29):3412-9. ttps://doi.org/10.1016/j.vaccine.2016.04.004
22. Benard S, Wright C, Voisine J, et al. Lifetime cost of meningococcal disease in France: Scenarios of severe meningitis and septicemia with purpura fulminans. Infection and Public Health. 2016;9(3):339-47. https://doi.org/10.1016/j.jiph.2015.10.016
23. Beck E, Klint J, Neine M, et al. Cost-effectiveness of 4CMenB infant vaccination in england: a comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24:91-104. doi: 10.1016/j.jval.2020.09.004
24. Gasparini R, Landa P, Amicizia D, et al. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero(R)) against meningococcal B disease: a cost-effectivene analysis. Human Vaccines & Immunotherapeutics. 2016;12:2148-61. doi: 10.1080/21645515.2016.1160177
Review
For citations:
Sergienko E.N., Kozhanova I.N., Romanova O.N., Solodov A.D., Sсutova P.A. Economic Burden of Invasive Meningococcal Infection in Children in the Republic of Belarus. Epidemiology and Vaccinal Prevention. 2023;22(6):99-107. (In Russ.) https://doi.org/10.31631/2073-3046-2023-22-6-99-107